APRE Aprea Therapeutics

Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference

Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference

DOYLESTOWN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that management will attend the 2024 RBC Capital Markets Global Healthcare Conference that will take place May 14-15, 2024 in New York, NY. Details are as follows:

2024 RBC Capital Markets Global Healthcare Conference
Date:May 14-15, 2024
Location:New York, NY
  

Management will be available for one-on-one meetings. To request a meeting, please contact your conference representative.

About Aprea

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Doylestown, Pennsylvania, focused on precision oncology through synthetic lethality. The Company’s lead program is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. Aprea has completed all IND-enabling studies for its oral, small molecule WEE1 inhibitor, APR-1051, and recently received FDA clearance of its IND. For more information, please visit the company website at

The Company may use, and intends to use, its investor relations website at / as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

Investor Contact:

Mike Moyer

LifeSci Advisors



EN
13/05/2024

Underlying

APREAprea Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aprea Therapeutics

 PRESS RELEASE
Free
APRE Aprea Therapeut...

Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase ...

Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051 APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet medical need Dosing of the first patient in the ACESOT-1051 study represents a key advancement in Aprea’s clinical pipeline DOYLESTOWN, Pa., June 17, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceut...

June 17, 2024 1 EN
 PRESS RELEASE
Free
APRE Aprea Therapeut...

Aprea Therapeutics Announces that Safety Review Committee (SRC) Endors...

Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial ATRN-119 is the first and only macrocyclic ATR inhibitor in the clinic, with best in class potential On track to complete dose escalation in ABOYA-119 clinical trial and potentially generate initial human efficacy data in 2H 2024 Through the first 5 cohorts, ATRN-119 has been found to be safe and well tolerated with no dose limiting toxicities (DLTs) observed DOYLESTOWN, Pa., May 28, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutic...

May 28, 2024 1 EN
Ritika Das ... (+3)
  • Ritika Das
  • Robert Driscoll
  • Sam Ravina
APRE APREA THERAPEUTICS
05/14/24 May 14, 2024 1 EN
 PRESS RELEASE
Free
APRE Aprea Therapeut...

Aprea Therapeutics Reports First quarter 2024 Financial Results and Pr...

Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update U.S. FDA cleared IND for APR-1051, a highly selective and potentially best-in-class oral WEE1 inhibitor; Company plans to initiate Phase 1 ACESOT-1051 clinical trial in June 2024 First-in-class macrocyclic ATR inhibitor, ATRN-119, on track to complete dose escalation in ABOYA-119 clinical trial and potentially generate initial human efficacy data in 2H 2024 Company had four poster presentations at the AACR Annual Meeting, including updates on APR-1051 and ATRN-119 $32.4 millio...

May 14, 2024 1 EN
 PRESS RELEASE
Free
APRE Aprea Therapeut...

Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healt...

Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference DOYLESTOWN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that management will attend the 2024 RBC Capital Markets Global Healthcare Conference that will take place May 14-15, 2024 in New York, NY. Details are as follows: 2024 RBC Capital Markets Global Healthcare ConferenceDate:May 14-15, 2024Location:New York, NY   Management ...

May 13, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch